{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:21:42Z","timestamp":1794547302968,"version":"4.9.1"},"reference-count":64,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["GT12053"],"award-info":[{"award-number":["GT12053"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI176834"],"award-info":[{"award-number":["R01 AI176834"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BRAUNS21P0"],"award-info":[{"award-number":["BRAUNS21P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HATFUL19GO"],"award-info":[{"award-number":["HATFUL19GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM116884"],"award-info":[{"award-number":["GM116884"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emily?s Entourage","award":["AWD00006613"],"award-info":[{"award-number":["AWD00006613"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bacteriophage therapy is being explored as an alternate therapeutic approach for treating drug-resistant bacteria, including mycobacteria. However, rational phage dosing remains limited by scarce pharmacokinetic (PK) data and an incomplete understanding of tissue distribution. We performed dose-ranging studies in mice of three therapeutic mycobacteriophages (BPs\u0394, ZoeJ\u0394, Muddy) after intravenous (IV) and intratracheal (IT) administration. All phages behaved similarly. IV dosing produced biphasic kinetics with nonproportional exposure and declining tissue-to-plasma ratios, indicating saturable uptake and elimination. IT delivery yielded monophasic profiles with \u223c390-fold higher lung exposure and \u223c490-fold lower plasma exposure, supporting inhaled therapy for pulmonary mycobacterial infections. Using BPs\u0394 data, we developed a mechanistic PBPK model incorporating transcytosis, saturable host clearance, plasma elimination, and lymphatic transport. The model accurately predicted ZoeJ\u0394 and Muddy PK, enabled cross-species extrapolation, and showed that phage morphology influences disposition. This framework advances phage therapy toward model-informed, exposure-guided dose and route selection for multidrug-resistant bacterial infections.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00604","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:02:16Z","timestamp":1789606936000},"page":"4998-5011","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Physiologically Based Pharmacokinetic Modeling of Mycobacteriophages: Insights into Pulmonary Distribution and Clearance"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-7548","authenticated-orcid":true,"given":"Rajnikant","family":"Sharma","sequence":"first","affiliation":[{"name":"University of Southern California , , , ,","place":["Los Angeles, California, United States, 90033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"University of Southern California , , , ,","place":["Los Angeles, California, United States, 90033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Divyash","sequence":"additional","affiliation":[{"name":"University of Southern California , , , ,","place":["Los Angeles, California, United States, 90033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Yeshwante","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikumar","family":"Matcha","sequence":"additional","affiliation":[{"name":"University of Southern California , , , ,","place":["Los Angeles, California, United States, 90033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChunFu","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of Southern California , , , ,","place":["Los Angeles, California, United States, 90033"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter S.","family":"Talley","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan A.","family":"Schmalstig","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Neupane","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-0550","authenticated-orcid":true,"given":"Sara E.","family":"Maloney Norcross","sequence":"additional","affiliation":[{"name":"RTI International , , , ,","place":["Durham, North Carolina, United States, 27713"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[{"name":"RTI International , , , ,","place":["Durham, North Carolina, United States, 27713"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham F.","family":"Hatfull","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , , , ,","place":["Pittsburgh, Pennsylvania, United States, 15260"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Braunstein","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]},{"name":"Colorado State University , , , ,","place":["Fort Collins, Colorado, United States, 80202"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-7770","authenticated-orcid":true,"given":"Gauri G.","family":"Rao","sequence":"additional","affiliation":[{"name":"University of Southern California , , , ,","place":["Los Angeles, California, United States, 90033"]},{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"8031","key":"2026100509320588500_cit1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/d41586-024-03033-w","article-title":"40 million deaths by 2050: toll of drug-resistant infections to rise by 70%","volume":"633","author":"Naddaf","year":"2024","journal-title":"Nature"},{"issue":"10459","key":"2026100509320588500_cit2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u22122021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"2026100509320588500_cit3","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3390\/jcm9082541","article-title":"General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus","volume":"9","author":"To","year":"2020","journal-title":"J. Clin. Med."},{"key":"2026100509320588500_cit4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"2026100509320588500_cit5","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"2026100509320588500_cit6","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti\u2212tumor necrosis factor-\u03b1 therapy","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerging Infect. Dis."},{"issue":"7","key":"2026100509320588500_cit7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010\u22122014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"6","key":"2026100509320588500_cit8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197976","article-title":"Epidemiology of nontuberculous mycobacterial infections in the US Veterans Health Administration","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"2026100509320588500_cit9","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin. Chest Med."},{"issue":"1","key":"2026100509320588500_cit10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1164\/rccm.202307-1165OC","article-title":"Five-year outcomes among US bronchiectasis and NTM research registry patients","volume":"210","author":"Aksamit","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"2026100509320588500_cit11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055672","article-title":"Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006\u22122021: a systematic review and meta-analysis","volume":"12","author":"Zhou","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"2026100509320588500_cit12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J. Cystic Fibrosis"},{"issue":"1","key":"2026100509320588500_cit13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1186\/s12879-024-09965-y","article-title":"Nontuberculous mycobacterial pulmonary disease (NTM PD) incidence trends in the United States, 2010\u22122019","volume":"24","author":"Bents","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"2026100509320588500_cit14","doi-asserted-by":"publisher","first-page":"1331508","DOI":"10.3389\/fmicb.2024.1331508","article-title":"Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches","volume":"15","author":"Nguyen","year":"2024","journal-title":"Front. Microbiol."},{"issue":"5","key":"2026100509320588500_cit15","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1093\/cid\/ciaf547","article-title":"The Role of \u03b2-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials","volume":"82","author":"Dousa","year":"2025","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"2026100509320588500_cit16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1164\/rccm.201807-1273PP","article-title":"Advancing translational science for pulmonary nontuberculous mycobacterial infections. A road map for research","volume":"199","author":"Daniel-Wayman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"23","key":"2026100509320588500_cit17","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.3390\/ijms20235868","article-title":"Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients","volume":"20","author":"Degiacomi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"2026100509320588500_cit18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/QCO.0000000000000104","article-title":"Mycobacterium abscessus: challenges in diagnosis and treatment","volume":"27","author":"Benwill","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"4","key":"2026100509320588500_cit19","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"2026100509320588500_cit20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","article-title":"Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease","volume":"76","author":"Dedrick","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"2026100509320588500_cit21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s41030-022-00210-y","article-title":"Phage therapy for nontuberculous mycobacteria: challenges and opportunities","volume":"9","author":"Hatfull","year":"2023","journal-title":"Pulm. Ther."},{"issue":"Supplement_5","key":"2026100509320588500_cit22","doi-asserted-by":"publisher","first-page":"S395","DOI":"10.1093\/cid\/ciad516","article-title":"Pharmacokinetic and pharmacodynamic obstacles for phage therapy from the perspective of clinical practice","volume":"77","author":"Mie\u0328dzybrodzki","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"14","key":"2026100509320588500_cit23","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34849","article-title":"Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections","volume":"10","author":"Guo","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"2026100509320588500_cit24","doi-asserted-by":"publisher","DOI":"10.2174\/0118742858281566231221045303","article-title":"Phage therapy: clinical applications, efficacy, and implementation hurdles","volume":"18","author":"Fowoyo","year":"2024","journal-title":"Open Microbiol. J."},{"issue":"1","key":"2026100509320588500_cit25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cpt.3426","article-title":"Crossing the Chasm: How to Approach Translational Pharmacokinetic\u2212Pharmacodynamic Modeling of Phage Dosing","volume":"117","author":"Rao","year":"2025","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"11","key":"2026100509320588500_cit26","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"Nick","year":"2022","journal-title":"Cell"},{"issue":"8","key":"2026100509320588500_cit27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat. Med."},{"key":"2026100509320588500_cit28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac194","article-title":"Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease","volume-title":"Open Forum Infectious Diseases","author":"Dedrick","year":"2022"},{"issue":"5","key":"2026100509320588500_cit29","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"2026100509320588500_cit30","doi-asserted-by":"publisher","first-page":"10C. 1.1","DOI":"10.1002\/9780471729259.mc10c01s14","article-title":"Laboratory maintenance of Mycobacterium smegmatis","volume":"14","author":"Singh","year":"2009","journal-title":"Curr. Protoc. Microbiol."},{"issue":"7","key":"2026100509320588500_cit31","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.chom.2023.05.028","article-title":"Virion glycosylation influences mycobacteriophage immune recognition","volume":"31","author":"Freeman","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"1","key":"2026100509320588500_cit32","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02924-23","article-title":"Bacteriophage infection and killing of intracellular Mycobacterium abscessus","volume":"15","author":"Schmalstig","year":"2024","journal-title":"mBio"},{"key":"2026100509320588500_cit33","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.2261","article-title":"Phage on tap\u2212a quick and efficient protocol for the preparation of bacteriophage laboratory stocks","volume":"4","author":"Bonilla","year":"2016","journal-title":"PeerJ"},{"issue":"8","key":"2026100509320588500_cit34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1152\/physiolgenomics.00185.2011","article-title":"Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstruction","volume":"44","author":"Livraghi-Butrico","year":"2012","journal-title":"Physiol. Genomics"},{"issue":"1","key":"2026100509320588500_cit35","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1038\/s41598-020-60452-1","article-title":"A mouse model of pulmonary Mycobacteroides abscessus infection","volume":"10","author":"Maggioncalda","year":"2020","journal-title":"Sci. Rep."},{"key":"2026100509320588500_cit36","unstructured":"D\u2019Argenio, D. Z.; Schumitzky, A.; Wang, X.\n          ADAPT 5 User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software; Biomedical Simulations Resource: Los Angeles, 2009."},{"issue":"12","key":"2026100509320588500_cit37","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","article-title":"Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial","volume":"24","author":"Kim","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"2026100509320588500_cit38","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00381-24","article-title":"Efficacies of omadacycline+ amikacin+ imipenem and an all-oral regimen omadacycline+ clofazimine+ linezolid in a mouse model of M. abscessus lung disease","volume":"9","author":"Ignatius","year":"2024","journal-title":"mSphere"},{"key":"2026100509320588500_cit39","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1016\/S1569-1993(11)60021-0","article-title":"The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease","volume":"10","author":"Zhou","year":"2011","journal-title":"J. Cystic Fibrosis"},{"issue":"5","key":"2026100509320588500_cit40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nm1028","article-title":"Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice","volume":"10","author":"Mall","year":"2004","journal-title":"Nat. Med."},{"key":"2026100509320588500_cit41","doi-asserted-by":"publisher","first-page":"114708","DOI":"10.1016\/j.addr.2023.114708","article-title":"Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles","volume":"194","author":"Kumar","year":"2023","journal-title":"Adv. Drug Delivery Rev."},{"issue":"6","key":"2026100509320588500_cit42","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01874-17","article-title":"Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers","volume":"8","author":"Nguyen","year":"2017","journal-title":"mBio"},{"issue":"1","key":"2026100509320588500_cit43","doi-asserted-by":"publisher","first-page":"17559","DOI":"10.1038\/s41598-018-35859-6","article-title":"Engineered K1F bacteriophages kill intracellular Escherichia coli K1 in human epithelial cells","volume":"8","author":"M\u00f8ller-Olsen","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"2026100509320588500_cit44","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/s41467-017-02057-3","article-title":"Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells","volume":"8","author":"Lehti","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"2026100509320588500_cit45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01470-20","article-title":"Pharmacokinetics and time-kill study of inhaled antipseudomonal bacteriophage therapy in mice","volume":"65","author":"Chow","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"2026100509320588500_cit46","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cmi.2020.04.039","article-title":"Pharmacokinetics\/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study","volume":"26","author":"Lin","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"2026100509320588500_cit47","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01359-23","article-title":"Evaluation of the impact of repeated intravenous phage doses on mammalian host\u2212phage interactions","volume":"98","author":"Tan","year":"2024","journal-title":"J. Virol."},{"issue":"4","key":"2026100509320588500_cit48","doi-asserted-by":"publisher","first-page":"102287","DOI":"10.1016\/j.isci.2021.102287","article-title":"Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy","volume":"24","author":"Bichet","year":"2021","journal-title":"iScience"},{"issue":"2","key":"2026100509320588500_cit49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/BF02880095","article-title":"The elimination of bacteriophages \u03a6X 174 and T2 from the circulating blood of newborn precolostral pigs","volume":"15","author":"Ha\u0301jek","year":"1970","journal-title":"Folia Microbiol."},{"issue":"6","key":"2026100509320588500_cit50","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat. Microbiol."},{"issue":"1","key":"2026100509320588500_cit51","doi-asserted-by":"publisher","first-page":"14802","DOI":"10.1038\/srep14802","article-title":"Mammalian Host-Versus-Phage immune response determines phage fate in vivo","volume":"5","author":"Hodyra-Stefaniak","year":"2015","journal-title":"Sci. Rep."},{"issue":"20","key":"2026100509320588500_cit52","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1016\/j.biomaterials.2012.03.054","article-title":"Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection","volume":"33","author":"Bhattarai","year":"2012","journal-title":"Biomaterials"},{"issue":"3","key":"2026100509320588500_cit53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/03009749209095084","article-title":"A five day course of high dose corticosteroids has no effect on the clearance of soluble aggregates of human immunoglobulin G in healthy volunteers","volume":"21","author":"Halma","year":"1992","journal-title":"Scand. J. Rheumatol."},{"issue":"4","key":"2026100509320588500_cit54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/pharmaceutics11040179","article-title":"Biodistribution and physiologically-based pharmacokinetic modeling of gold nanoparticles in mice with interspecies extrapolation","volume":"11","author":"Aborig","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026100509320588500_cit55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.xphs.2023.10.005","article-title":"Whole-body disposition and physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product","volume":"113","author":"Liu","year":"2024","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"2026100509320588500_cit56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12985-024-02552-2","article-title":"Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery","volume":"22","author":"Smytheman","year":"2025","journal-title":"Virol. J."},{"issue":"1","key":"2026100509320588500_cit57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12989-022-00489-4","article-title":"Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats","volume":"19","author":"Chou","year":"2022","journal-title":"Part. Fibre Toxicol."},{"issue":"5","key":"2026100509320588500_cit58","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK modeling and simulation in drug research and development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"2026100509320588500_cit59","doi-asserted-by":"publisher","first-page":"2025.02.06.636931","DOI":"10.1101\/2025.02.06.636931","article-title":"Whole-Body Bacteriophage Distribution Characterized by a Physiologically Based Pharmacokinetic Model","author":"Echterhof","year":"2025","journal-title":"bioRxiv"},{"issue":"20","key":"2026100509320588500_cit60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.181309","article-title":"The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo","volume":"9","author":"Echterhof","year":"2024","journal-title":"JCI Insight"},{"issue":"5","key":"2026100509320588500_cit61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1751-7915.2011.00259.x","article-title":"Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens","volume":"4","author":"Kvachadze","year":"2011","journal-title":"Microb. Biotechnol."},{"key":"2026100509320588500_cit200","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12985-024-02552-2","article-title":"Evaluation of host immune responses to mycobacteriophage Fionnbharth by route of delivery","volume":"22","author":"Smytheman","year":"2025","journal-title":"Journal of Virology"},{"issue":"7","key":"2026100509320588500_cit62","doi-asserted-by":"publisher","first-page":"110825","DOI":"10.1016\/j.celrep.2022.110825","article-title":"Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy","volume":"39","author":"Delattre","year":"2022","journal-title":"Cell Rep."},{"issue":"3","key":"2026100509320588500_cit63","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00604","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4998\/68745736\/mp6c00604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4998\/68745736\/mp6c00604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:20:37Z","timestamp":1794543637000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/4998\/5431723\/Pharmacokinetics-and-Physiologically-Based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,17]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00604","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00604.s002","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}